“`html
Alcon Inc. has received approval from Health Canada for its ALC UNITY Vitreoretinal Cataract System (VCS). The company plans to commercially launch the UNITY VCS in early 2026, enhancing its Surgical segment and driving efficiencies for eye care professionals.
Following the announcement, Alcon’s shares increased by 0.3% in trading, although the year-to-date gain stands at 2.6% compared to a 9.2% industry decline. Alcon’s current market capitalization is $42.93 billion, with Q1 2025 R&D spending rising 11.6% year over year.
UNITY VCS promises significant advances with features like phacoemulsification that enables two times faster nucleus removal with 40% less energy and a vitrectomy probe capable of 30,000 cuts per minute. Alcon conducted tests with over 200 surgeons from more than 30 countries before the approval.
“`
